Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim N Chi

Showing results (1-10 of 234) with videos related to

Pageof 24
Sort By:
World Journal of Urology|February 22, 2005
Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancerKim N Chi
Future Oncology (London, England)|November 8, 2012
Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancerRobert Zielinski, Kim N Chi
Annals of the New York Academy of Sciences|January 6, 2006
Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancersMartin Gleave, Kim N Chi
International Journal of Urology : Official Journal of the Japanese Urological Association|June 28, 2016
Chemotherapy for metastatic castration-sensitive prostate cancerSunil Parimi, Kim N Chi
The Urologic Clinics of North America|February 16, 2010
Novel targeted therapies for prostate cancerRobyn J Macfarlane, Kim N Chi
Current Opinion in Supportive and Palliative Care|August 8, 2008
Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancerEmma K Beardsley, Kim N Chi
Expert Opinion on Biological Therapy|June 4, 2004
Antisense approaches in prostate cancerKim N Chi, Martin E Gleave
The Journal of Urology|August 13, 2003
Asian race and impact on outcomes after radical radiotherapy for localized prostate cancerAda Man, Tom Pickles, Kim N Chi, et al.
The Canadian Journal of Urology|December 26, 2006
Prednisone monotherapy in asymptomatic hormone refractory prostate cancerDaniel Y C Heng, Kim N Chi
Expert Opinion on Investigational Drugs|November 18, 2008
Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancerKim N Chi, Amina Zoubeidi, Martin E Gleave
Pageof 24

Showing results (1-10 of 234) with videos related to

Sort By:
Pageof 24
World Journal of Urology|February 22, 2005
Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancerKim N Chi
Future Oncology (London, England)|November 8, 2012
Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancerRobert Zielinski, Kim N Chi
Annals of the New York Academy of Sciences|January 6, 2006
Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancersMartin Gleave, Kim N Chi
International Journal of Urology : Official Journal of the Japanese Urological Association|June 28, 2016
Chemotherapy for metastatic castration-sensitive prostate cancerSunil Parimi, Kim N Chi
The Urologic Clinics of North America|February 16, 2010
Novel targeted therapies for prostate cancerRobyn J Macfarlane, Kim N Chi
Current Opinion in Supportive and Palliative Care|August 8, 2008
Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancerEmma K Beardsley, Kim N Chi
Expert Opinion on Biological Therapy|June 4, 2004
Antisense approaches in prostate cancerKim N Chi, Martin E Gleave
The Journal of Urology|August 13, 2003
Asian race and impact on outcomes after radical radiotherapy for localized prostate cancerAda Man, Tom Pickles, Kim N Chi, et al.
The Canadian Journal of Urology|December 26, 2006
Prednisone monotherapy in asymptomatic hormone refractory prostate cancerDaniel Y C Heng, Kim N Chi
Expert Opinion on Investigational Drugs|November 18, 2008
Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancerKim N Chi, Amina Zoubeidi, Martin E Gleave
Pageof 24